Australia markets closed

Virios Therapeutics, Inc. (VIRI)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.9400-0.2900 (-6.86%)
At close: 04:00PM EDT
4.0000 +0.06 (+1.52%)
After hours: 04:20PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 36.25M
Enterprise value 39.97M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)3.40
Enterprise value/revenue N/A
Enterprise value/EBITDA -2.42

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-32.10%
S&P500 52-week change 3-13.03%
52-week high 37.2100
52-week low 33.3000
50-day moving average 34.1165
200-day moving average 35.0433

Share statistics

Avg vol (3-month) 315.07k
Avg vol (10-day) 320.28k
Shares outstanding 58.33M
Implied shares outstanding 6N/A
Float 86.63M
% held by insiders 111.20%
% held by institutions 113.18%
Shares short (14 June 2022) 447.99k
Short ratio (14 June 2022) 43.38
Short % of float (14 June 2022) 40.73%
Short % of shares outstanding (14 June 2022) 40.58%
Shares short (prior month 12 May 2022) 444.78k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Mar 2022


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-50.66%
Return on equity (ttm)-89.28%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
Net income avi to common (ttm)-16.86M
Diluted EPS (ttm)-2.0240
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)11.35M
Total cash per share (mrq)1.36
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)6.68
Book value per share (mrq)1.28

Cash flow statement

Operating cash flow (ttm)-13.23M
Levered free cash flow (ttm)-6.71M